AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
AAPL   372.69 (-0.31%)
MSFT   208.25 (-1.16%)
FB   240.86 (+0.24%)
AMZN   3,000.12 (-1.86%)
NVDA   394.87 (+0.33%)
CGC   16.50 (-2.60%)
BABA   236.51 (-1.45%)
MU   49.09 (-3.59%)
TSLA   1,389.86 (+1.33%)
AMD   52.93 (-0.88%)
T   30.32 (-0.56%)
ACB   12.42 (+1.97%)
F   6.12 (-1.13%)
GILD   76.42 (-0.44%)
DIS   113.63 (-0.69%)
BAC   23.01 (-2.75%)
NFLX   493.16 (-0.13%)
BA   178.88 (-4.81%)
Log in

CVE:KNEKane Biotech Stock Price, Forecast & News

C$0.14
+0.01 (+3.57 %)
(As of 07/7/2020 04:00 PM ET)
Add
Compare
Today's Range
C$0.15
Now: C$0.15
C$0.15
50-Day Range
C$0.14
MA: C$0.15
C$0.19
52-Week Range
C$0.09
Now: C$0.15
C$0.26
Volume3,000 shs
Average Volume89,736 shs
Market CapitalizationC$15.75 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kane Biotech Inc., a biotechnology company, researches, develops, and commercializes technologies and products that prevent and remove microbial biofilms worldwide. It develops pet oral care solutions under the StrixNB and bluestem trademarks; animal and human wound care solutions under the DispersinB trademark; medical device coatings under the Aledex trademark; and shampoo for dogs, cats, and horses under the Alosera trademark. The company was founded in 2001 and is based in Winnipeg, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.42 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-204-4531301

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$1.53 million
Cash FlowC$0.00 per share
Book ValueC$0.01 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$15.75 million
Next Earnings Date8/19/2020 (Estimated)
OptionableNot Optionable

Receive KNE News and Ratings via Email

Sign-up to receive the latest news and ratings for KNE and its competitors with MarketBeat's FREE daily newsletter.

Kane Biotech (CVE:KNE) Frequently Asked Questions

How has Kane Biotech's stock been impacted by COVID-19 (Coronavirus)?

Kane Biotech's stock was trading at C$0.18 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KNE shares have decreased by 19.4% and is now trading at C$0.15. View which stocks have been most impacted by Coronavirus.

When is Kane Biotech's next earnings date?

Kane Biotech is scheduled to release its next quarterly earnings announcement on Wednesday, August 19th 2020. View our earnings forecast for Kane Biotech.

How were Kane Biotech's earnings last quarter?

Kane Biotech Inc (CVE:KNE) released its quarterly earnings data on Thursday, May, 21st. The company reported ($0.01) EPS for the quarter. The company earned $0.46 million during the quarter. View Kane Biotech's earnings history.

Has Kane Biotech been receiving favorable news coverage?

Headlines about KNE stock have trended negative this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Kane Biotech earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Kane Biotech.

Who are some of Kane Biotech's key competitors?

Who are Kane Biotech's key executives?

Kane Biotech's management team includes the following people:
  • Mr. Marc Edwards, Interim CEO & Director
  • Mr. Ray Dupuis, Chief Financial Officer
  • Mr. Mark Ahrens-Townsend, Advisor
  • Dr. Gordon Guay, Chief Scientific Officer & Member of Scientific Advisory Board
  • Mr. L. Michael Coutts, Director of Bus. Devel.

What is Kane Biotech's stock symbol?

Kane Biotech trades on the Canadian Venture Exchange (CVE) under the ticker symbol "KNE."

How do I buy shares of Kane Biotech?

Shares of KNE and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Kane Biotech's stock price today?

One share of KNE stock can currently be purchased for approximately C$0.15.

How big of a company is Kane Biotech?

Kane Biotech has a market capitalization of C$15.75 million and generates C$1.53 million in revenue each year.

What is Kane Biotech's official website?

The official website for Kane Biotech is www.kanebiotech.com.

How can I contact Kane Biotech?

Kane Biotech's mailing address is 162-196 Innovation Dr, WINNIPEG, MB R3T 6C5, Canada. The company can be reached via phone at +1-204-4531301.

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.